WallStSmart

ResMed Inc (RMD)vsAT&T Inc. (T)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AT&T Inc. generates 2185% more annual revenue ($126.53B vs $5.54B). RMD leads profitability with a 27.4% profit margin vs 16.9%. RMD appears more attractively valued with a PEG of 1.23. RMD earns a higher WallStSmart Score of 73/100 (B).

RMD

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 5.3Quality: 8.3
Piotroski: 6/9Altman Z: 4.34

T

Buy

64

out of 100

Grade: C+

Growth: 3.3Profit: 7.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RMDOvervalued (-13.1%)

Margin of Safety

-13.1%

Fair Value

$229.58

Current Price

$206.76

$22.82 premium

UndervaluedFair: $229.58Overvalued
TUndervalued (+21.5%)

Margin of Safety

+21.5%

Fair Value

$32.17

Current Price

$25.16

$7.01 discount

UndervaluedFair: $32.17Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.3%10/10

Strong operational efficiency at 35.3%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.3%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
27.4%9/10

Keeps 27 of every $100 in revenue as profit

T5 strengths · Avg: 8.6/10
P/E RatioValuation
8.3x10/10

Attractively priced relative to earnings

Market CapQuality
$175.52B9/10

Large-cap with strong market position

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.7%8/10

Strong operational efficiency at 22.7%

Free Cash FlowQuality
$2.68B8/10

Generating 2.7B in free cash flow

Areas to Watch

RMD0 concerns · Avg: 0/10

No major concerns identified

T3 concerns · Avg: 3.3/10
PEG RatioValuation
1.814/10

Expensive relative to growth rate

Revenue GrowthGrowth
2.9%4/10

2.9% revenue growth

EPS GrowthGrowth
-11.3%2/10

Earnings declined 11.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.

Bull Case : T

The strongest argument for T centers on P/E Ratio, Market Cap, Price/Book. Profitability is solid with margins at 16.9% and operating margin at 22.7%.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Bear Case : T

The primary concerns for T are PEG Ratio, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

RMD profiles as a mature stock while T is a value play — different risk/reward profiles.

RMD carries more volatility with a beta of 0.84 — expect wider price swings.

RMD is growing revenue faster at 10.8% — sustainability is the question.

T generates stronger free cash flow (2.7B), providing more financial flexibility.

Bottom Line

RMD scores higher overall (73/100 vs 64/100), backed by strong 27.4% margins and 10.8% revenue growth. T offers better value entry with a 21.5% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

AT&T Inc.

COMMUNICATION SERVICES · TELECOM SERVICES · USA

AT&T Inc. is an American multinational conglomerate holding company, Delaware-registered but headquartered at Whitacre Tower in Downtown Dallas, Texas. It is the world largest telecommunications company, and the second largest provider of mobile telephone services.

Want to dig deeper into these stocks?